2002, Number S1
<< Back Next >>
Arch Cardiol Mex 2002; 72 (S1)
Pharmacology of inotropic egents
Pastelín HG
Language: Spanish
References: 10
Page: 156-162
PDF size: 79.06 Kb.
ABSTRACT
High-risk patients, during anesthesia and after surgery present changes in pharmacokinetics (biotransformation reactions, renal clearance, drug interactions, etc.) modifying the usefulness of most drugs, cardiac inotropics included. This group of substances is formed by adrenergic agents, phospodiesterase inhibitors and digitalis compounds. Adrenergic agents are the catecholamines, adrenaline (A), noradrenaline (NA) and dopamine (D), plus dopaminergic agonists as dobutamine and pirbuterol. Phosphodiesterase inhibitors, as amrinone and milrinone, produce their inotropic action by preserving cyclic adenosine monophosphate (AMPc) from its intracellular catabolism. Recent studies on the utility of digitalis compounds demonstrated the valuable applicability of digoxin in chronic and acute heart failure. Another group of substances whose mechanism of action differs from that of the inotropics, offers future utility in high risk patients, they include: inhibitors of nitric oxide sintases, natriuretic atrial peptide inhibitors, Q-10 coenzyme, endothelin antagonists, and anti-tumoral necrosis factor.
REFERENCES
Remme WJ, Swedberg K: Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001; 22: 1527-1560.
MacGowan GA, Du C, Koretzky AP: High calcium and dobutamine positive inotropy in the perfused mouse heart: myofilament calcium responsiveness, energetic economy, and effects of protein kinase C. BMC Physiol 2001; 1(1): 12.
Gómez AM, Valdivia HH, Cheng H, Lederer MR, Santana LF, Cannell MB, et al: Defective excitation-contraction coupling in experimental cardiac hypertrophy and heart failure. Science 1997; 276: 800-806.
Ramahi TM, Longo MD, Cadariu AR, Rohlfs K, Slade M, Carolan S, et al: Dobutamine-induced aumentation of left ventricular ejection fraction predicts survival of heart failure patients with left severe non-ischemic cardiomyopathy. Eur Heart J 2001; 22: 849-856.
The Digitalis Investigation Group (DIG): The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336: 525-533.
Rich MW, McSherry F, Williford WO, Yusuf S: Effect of age on mortality, hospitalizations and response to digoxin in patients with heart failure: the DIG study. J Am Coll Cardiol 2001; 38: 806-813.
Chavey WE, Blaum Cs, Bleske BE, Van Harrison R, Kesterson S, Nickas JM: Guideline for the management of heart failure caused by systolic disfunction: part II. Treatment. Am Fam Physician 2001; 64: 1045-1054.
Sear JW, Howell SJ, Sear YM, Yeates D, Goldacre M, Foex P: Intercurrent drug therapy and perioperative cardiovascular mortality in elective and urgent/emergency surgical patients. Br J Anaesth 2001; 86: 506-512.
Méndez R, Pastelin G, Kabela E: The influence of the position of attachment of the lactone ring to the steroid nucleus on the action of cardiac glycosides. J Pharmacol Exp Ther 1973; 188: 189-197.
Wasserstrom JA, Farkas D, Norell M, Vereault DV: Effects of different cardiac steroids on intracellular sodium inotropy and toxicity in sheep Purkinje fibers. J Pharmacol Exp Ther 1991; 258: 918-925.
Full text